Justin P Turner1, Claude Richard2, Marie-Thérèse Lussier3, Marie-Eve Lavoie2, Barbara Farrell4, Denis Roberge5, Cara Tannenbaum6. 1. Facultés de Pharmacie, Université de Montréal Research Center of Institut Universitaire de Gériatrie de Montréal, Québec, Canada. 2. Équipe de Recherche en Soins de Première Ligne, Centre Intégré de Santé et de Services Sociaux de Laval, Québec, Canada. 3. Département de Médecine de Famille et de Médecine d'Urgence, Université de Montréal, Montréal, Québec, CanadaÉquipe de Recherche en Soins de Première Ligne, Centre Intégré de Santé et de Services Sociaux de Laval, Québec, Canada. 4. Geriatric Day Hospital, Bruyère Continuing Care, Bruyère Research Institute and CT Lamont Primary Health Care Research Centre, Ottawa, Ontario, Canada Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada. 5. Entre les Lignes Inc., Montréal, Canada. 6. Facultés de Médecine et de Pharmacie, Université de MontréalResearch Center of Institut Universitaire de Gériatrie de Montréal, Québec, Canada.
Abstract
BACKGROUND: Little is known about the initiation, style and content of patient and healthcare provider communication around deprescribing. We report the findings from a content analysis of audio-recorded discussions of proton pump inhibitor (PPI) and benzodiazepine deprescribing in primary care. METHODS: Participants were healthcare providers (n = 13) from primary care practices (n = 3) and patients aged ⩾65 (n = 24) who were chronic users of PPIs or benzodiazepines. The EMPOWER educational brochures were distributed prior to (n = 15) or after (n = 9) the patient's usual healthcare provider appointment. Conversations were audio-recorded and coded using MEDICODE to analyze who initiated different themes, whether they followed a monologue or dialogue style, and to what extent the thematic content addressed issues pertaining to: 'dosage/instructions,' 'medication action and efficacy,' 'risk/adverse effects,' 'attitudes/emotions,' 'adherence' and 'follow up.' Descriptive analysis of the conversations was performed with comparison between patients who received the EMPOWER brochure before or after their appointments. RESULTS: Patients were mostly women (67%) with a mean age of 74 ± 6 years. For PPI users, prior education resulted in a greater proportion of themes initiated by patients (44% versus 17%) and maintaining dialogue-style conversations (48% versus 28%). Among benzodiazepine users, conversation initiation (52% versus 47%) and conversation style was similar between both groups. The content of deprescribing conversations for PPIs revealed that patients and their healthcare providers focused less on 'dosage/instructions,' and more on the 'medication action and efficacy' and the necessity for 'follow up.' Conversations about stopping benzodiazepines were more likely to stagnate on the 'if' rather than the 'how.' CONCLUSION: The initiation, style and content of the conversations varied between PPI and benzodiazepine users, suggesting that healthcare providers will need to tailor deprescribing conversations accordingly.
BACKGROUND: Little is known about the initiation, style and content of patient and healthcare provider communication around deprescribing. We report the findings from a content analysis of audio-recorded discussions of proton pump inhibitor (PPI) and benzodiazepine deprescribing in primary care. METHODS: Participants were healthcare providers (n = 13) from primary care practices (n = 3) and patients aged ⩾65 (n = 24) who were chronic users of PPIs or benzodiazepines. The EMPOWER educational brochures were distributed prior to (n = 15) or after (n = 9) the patient's usual healthcare provider appointment. Conversations were audio-recorded and coded using MEDICODE to analyze who initiated different themes, whether they followed a monologue or dialogue style, and to what extent the thematic content addressed issues pertaining to: 'dosage/instructions,' 'medication action and efficacy,' 'risk/adverse effects,' 'attitudes/emotions,' 'adherence' and 'follow up.' Descriptive analysis of the conversations was performed with comparison between patients who received the EMPOWER brochure before or after their appointments. RESULTS: Patients were mostly women (67%) with a mean age of 74 ± 6 years. For PPI users, prior education resulted in a greater proportion of themes initiated by patients (44% versus 17%) and maintaining dialogue-style conversations (48% versus 28%). Among benzodiazepine users, conversation initiation (52% versus 47%) and conversation style was similar between both groups. The content of deprescribing conversations for PPIs revealed that patients and their healthcare providers focused less on 'dosage/instructions,' and more on the 'medication action and efficacy' and the necessity for 'follow up.' Conversations about stopping benzodiazepines were more likely to stagnate on the 'if' rather than the 'how.' CONCLUSION: The initiation, style and content of the conversations varied between PPI and benzodiazepine users, suggesting that healthcare providers will need to tailor deprescribing conversations accordingly.
Entities:
Keywords:
aged; decision-making; deprescribing; education; potentially inappropriate medication; primary health care; public health professional; shared
Authors: C Vicens; F Bejarano; E Sempere; C Mateu; F Fiol; I Socias; E Aragonès; V Palop; J L Beltran; J L Piñol; G Lera; S Folch; M Mengual; J Basora; M Esteva; J Llobera; M Roca; M Gili; A Leiva Journal: Br J Psychiatry Date: 2014-02-13 Impact factor: 9.319
Authors: Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell Journal: Can Fam Physician Date: 2018-05 Impact factor: 3.275
Authors: Taline A Boghossian; Farah Joy Rashid; Wade Thompson; Vivian Welch; Paul Moayyedi; Carlos Rojas-Fernandez; Kevin Pottie; Barbara Farrell Journal: Cochrane Database Syst Rev Date: 2017-03-16
Authors: A L Yailian; E Huet; B Charpiat; O Conort; M Juste; R Roubille; M Bourdelin; J Gravoulet; C Mongaret; C Vermorel; P Bedouch; A Janoly-Duménil Journal: Int J Clin Pract Date: 2022-06-28 Impact factor: 3.149
Authors: Karolina Kuberska; Fiona Scheibl; Carol Sinnott; James P Sheppard; Mark Lown; Marney Williams; Rupert A Payne; Jonathan Mant; Richard J McManus; Jenni Burt Journal: Br J Gen Pract Date: 2021-06-24 Impact factor: 6.302
Authors: Jose Ignacio de Juan-Roldán; Marcos Castillo-Jimena; Alba González-Hevilla; Clara Sánchez-Sánchez; Antonio J García-Ruiz; Enrique Gavilán-Moral Journal: BMJ Open Date: 2022-04-21 Impact factor: 3.006